Every Form 4 that Karyopharm Therapeutics Inc (KPTI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KPTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KPTI filings page.
Karyopharm Therapeutics Inc. (KPTI) disclosed that Chief Accounting Officer Kristin Abate sold 19 shares of common stock on September 1, 2026 at $2.02 per share. According to the disclosure, this broker-assisted sale was made under a durable automatic sale instruction plan to satisfy withholding tax liability from vesting restricted stock units and is described as non-discretionary. After the sale, Abate directly held 23,782 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Stuart Poulton, EVP and Chief Development Officer, reported the sale of 189 shares of common stock on July 28, 2026 at $7.10 per share.
The broker-assisted sale was made under a durable automatic sale instruction plan adopted on May 18, 2022 to satisfy withholding tax liability from vested restricted stock units and is described as non-discretionary; Poulton now holds 94,632 shares directly.
Karyopharm Therapeutics Inc. director Christy J. Oliger received an equity award in the form of 15,508 shares of Common Stock, reported as a grant of restricted stock units (RSUs) with a price of $0.00 per share as compensation rather than a market purchase.
The award was made under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, vesting 100% on May 21, 2027. However, actual share delivery is deferred until the earlier of the director’s separation from service or a qualifying change-in-control event, so the economic benefit is realized over time.
Karyopharm Therapeutics Inc. director Deepika Pakianathan received an equity award in the form of 15,508 restricted stock units, which convert into common stock on a one-for-one basis. The RSUs vest in full on May 21, 2027, with share delivery deferred until separation from service or a change-in-control event.
Karyopharm Therapeutics Inc. director Chen Schor reported an award of 15,508 shares of common stock in the form of restricted stock units (RSUs) granted at no cash cost as director compensation.
The RSUs were granted under the 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest 100% on May 21, 2027, with delivery of the underlying shares deferred until the earlier of Schor’s separation from service or a change-in-control event. The filing shows no open-market buying or selling, only a stock-based compensation grant resulting in direct ownership of 15,508 shares after the award.
Su Zhen reported acquisition or exercise transactions in this Form 4 filing.
Karyopharm Therapeutics Inc. director Su Zhen received a grant of 15,508 restricted stock units (RSUs) of common stock as equity compensation. The RSUs vest 100% on May 21, 2027, and delivery of the underlying shares is deferred until separation from service or a change-in-control event. Following this award, Su Zhen directly holds 15,508 shares/RSUs in total.
Karyopharm Therapeutics Inc. director Garen G. Bohlin received an award of 15,508 restricted stock units (RSUs) under the company’s 2022 Equity Incentive Plan. These RSUs will vest 100% on May 21, 2027 and convert into common stock on a one-for-one basis.
Delivery of the vested shares is deferred until the earlier of the director’s separation from service or a change-in-control event. Following this grant, Bohlin holds 18,517 shares of common stock. All amounts reflect Karyopharm’s one-for-fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics Inc. director Barry E. Greene reported an equity compensation grant. He received 15,508 restricted stock units (RSUs) of common stock at no cash cost under the company’s 2022 Equity Incentive Plan, as amended.
The RSUs convert into common stock on a one-for-one basis and vest 100% on May 21, 2027. Delivery of shares is deferred until the earlier of Greene’s separation from service or a change-in-control event. After this award, he holds 16,415 shares of common stock directly. All amounts reflect Karyopharm’s one-for-fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics EVP and Chief Development Officer Stuart Poulton reported a mix of equity award vesting and a related share sale. On May 13, 2026, he acquired 896 shares of common stock at $0.00 per share through earned performance-based restricted stock units tied to full enrollment of the Phase 3 XPORT-EC-042 trial. Those units vested the same day. On May 14, 2026, 403 shares were sold at $9.50 per share under a durable automatic sale instruction plan to cover withholding tax liabilities from the vesting, and the sale was not a discretionary trade. After these transactions, he directly owned 94,821 shares of common stock.
Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported routine equity compensation activity. On May 13, she acquired 947 shares of common stock at no cost from performance-based restricted stock units that vested after certification of a Phase 3 XPORT-EC-042 enrollment milestone. On May 14, 408 shares were sold at $9.50 per share under a durable automatic sale instruction plan adopted on April 4, 2022, solely to cover withholding tax obligations upon PSU vesting. Following these transactions, she directly holds 56,829 shares of common stock.
Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported two transactions in common stock. On May 13, 2026, she acquired 947 shares at no cost from performance-based restricted stock units earned after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified. On May 14, 2026, she sold 324 shares at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan to cover withholding tax from the PSU vesting, described as non-discretionary. Following these transactions, she directly owns 107,940 shares of Karyopharm common stock.
Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported a small set of routine equity transactions. On May 13, 2026, she acquired 121 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to completion of enrollment in the Company’s Phase 3 XPORT-EC-042 trial, which vested that day.
On May 14, 2026, 53 shares of common stock were sold at $9.50 per share in a broker-assisted transaction executed under a durable automatic sale instruction plan adopted on May 27, 2021, solely to satisfy withholding tax obligations from the PSU vesting, and not as a discretionary trade. After these transactions, Abate directly held 23,801 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported routine equity compensation activity. On May 13, 2026, he acquired 4,920 shares of common stock at $0.00 per share from earned performance-based restricted stock units tied to a Phase 3 XPORT-EC-042 clinical milestone. These earned PSUs vested the same day.
On May 14, 2026, Paulson sold 2,203 shares of common stock at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on June 10, 2021. The footnote states this sale was solely to satisfy withholding tax obligations from the PSU vesting and was not a discretionary trade. After these transactions, he directly held 269,747 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported a small automatic share sale tied to a performance-based equity award. On May 13, 2026, he acquired 700 shares of common stock via earned performance-based restricted stock units (PSUs) granted in February 2024, after a clinical enrollment milestone in the Phase 3 XPORT-EC-042 trial was certified as achieved.
On May 14, 2026, 266 shares of common stock were sold at $9.50 per share in a broker-assisted transaction under a durable automatic sale instruction plan adopted on May 16, 2022, solely to cover withholding tax liability from the PSU vesting. Following these transactions, Michael directly owns 94,398 shares of Karyopharm common stock.
Karyopharm Therapeutics EVP & Chief Medical Officer Reshma Rangwala reported a small, non-discretionary sale of common stock tied to taxes on vested equity. On April 21, 2026, a broker-assisted sale of 449 shares of common stock was executed at $8.94 per share.
According to the disclosure, this trade was carried out under a durable automatic sale instruction plan adopted on April 4, 2022 and was used to satisfy withholding tax liability from the vesting of restricted stock units. After this transaction, Rangwala directly holds 56,290 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported an open-market sale of 3,526 shares of common stock at an average price of $9.4095 per share. According to the disclosure, this broker-assisted sale was made under a durable automatic sale instruction plan and was used solely to cover withholding taxes triggered by the vesting of restricted stock units, rather than a discretionary trade. After this tax-related transaction, Michael held 93,964 shares of Karyopharm common stock directly.
Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported an open-market sale of 4,604 shares of common stock at $9.4095 per share. This broker-assisted sale was executed under a durable automatic sale instruction plan to cover withholding taxes on vested restricted stock units and was not a discretionary trade. After the transaction, Cheng directly holds 107,317 shares.
Karyopharm Therapeutics Inc. executive Reshma Rangwala, EVP & Chief Medical Officer, reported an open-market sale of 5,066 shares of common stock at an average price of $9.4095 per share. After this transaction, she held 56,739 shares directly.
According to the disclosure, the sale was executed under a pre-established durable automatic sale instruction plan adopted on April 4, 2022. The shares were sold by a broker to cover withholding tax obligations arising from the vesting of restricted stock units, and the filing states that the transaction did not represent a discretionary trade by the reporting person.
Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported an automatic sale of common stock under a pre-established durable automatic sale instruction plan. On this transaction date, he sold 12,361 shares of common stock at an average price of $9.4095 per share in a broker-assisted transaction to satisfy withholding tax obligations arising from the vesting of restricted stock units. Following this tax-related, non-discretionary sale, he continued to hold 267,030 shares of Karyopharm Therapeutics common stock directly.
Karyopharm Therapeutics Inc. executive Stuart Poulton, EVP and Chief Development Officer, reported an automatic sale of common stock to cover taxes tied to restricted stock units that vested. On this transaction date, he sold 5,101 shares in an open-market sale at an average price of $9.4095 per share under a durable automatic sale instruction plan adopted on May 18, 2022. The filing states this broker-assisted sale was executed to satisfy withholding tax liabilities and did not represent a discretionary trade by Poulton. Following the sale, he directly held 94,328 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. Chief Accounting Officer Kristin Abate reported an open-market sale of 559 shares of common stock at an average price of $9.4095 per share. After this transaction, she directly owns 22,063 shares. The sale was executed under a pre-established automatic plan solely to cover tax withholding on vested restricted stock units and was not a discretionary trade.
Karyopharm Therapeutics EVP and Chief Development Officer Poulton Stuart reported an automatic sale of company stock. On February 17, 2026, a broker-assisted transaction sold 378 shares of common stock at $8.63 per share to cover withholding taxes triggered by vesting restricted stock units.
The sale was executed under a durable automatic sale instruction plan adopted on May 18, 2022 and is described as non-discretionary for the insider. Following this tax-related sale, Poulton Stuart directly holds 99,429 shares of Karyopharm Therapeutics common stock.
Karyopharm Therapeutics Inc. reported that its President and CEO, Richard A. Paulson, received an award of 81,060 shares of common stock in the form of restricted stock units (RSUs) on February 5, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan and increase his directly held beneficial ownership to 279,391 shares of common stock.
The RSUs convert into common stock on a one-for-one basis. Vesting is scheduled so that 50% of the RSUs vest on January 31, 2027, with the remaining 50% vesting on January 31, 2028, tying a portion of the CEO’s compensation to the company’s long-term performance and continued service.
Karyopharm Therapeutics executive Lori Macomber reported an automatic tax-related stock sale. On 02/03/2026, the EVP, CFO & Treasurer sold 1,626 shares of Karyopharm Therapeutics Inc. common stock at $6.30 per share in a broker-assisted transaction tied to restricted stock unit vesting. After the sale, she directly beneficially owned 85,105 common shares. The filing explains the transaction was executed under a durable automatic sale instruction plan adopted on December 19, 2024, solely to cover withholding tax liabilities and did not represent a discretionary trade.
Karyopharm Therapeutics Inc. executive Sohanya Cheng, EVP & Chief Commercial Officer, received an award of 32,415 shares of common stock in the form of restricted stock units on January 31, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis, with 50% vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Cheng beneficially owns 111,921 shares of Karyopharm common stock in direct ownership.
Karyopharm Therapeutics reported that its EVP & Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units (RSUs) of common stock on January 31, 2026 at a price of $0 per share. The RSUs were granted under the company’s 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. Half of the shares vest on January 31, 2027, with the remaining half vesting on January 31, 2028. Following this award, Rangwala beneficially owns 61,805 shares of Karyopharm common stock directly.
Karyopharm Therapeutics Inc. reported an equity compensation award to its EVP, CFO & Treasurer, Lori Macomber. She received 32,415 restricted stock units (RSUs) of Karyopharm common stock at a grant price of $0.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal installments, with 50% vesting on January 31, 2027 and the remaining 50% on January 31, 2028. Following this grant, Macomber beneficially owns 86,731 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Michael Mano, EVP, CLO & Secretary, received an equity award of 32,415 shares of common stock on January 31, 2026. The award was granted at a price of $0 per share under the company’s 2022 Equity Incentive Plan as restricted stock units.
The RSUs convert into common stock on a one-for-one basis and vest over time, with 50% of the shares vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Mano directly beneficially owns 97,490 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive vice president and chief development officer Stuart Poulton reported an award of 32,415 shares of common stock on January 31, 2026. These were granted as restricted stock units under the company’s 2022 Equity Incentive Plan at a price of $0 per share.
The RSUs convert into common stock on a one-for-one basis. Half of the award is scheduled to vest on January 31, 2027, and the remaining half on January 31, 2028. Following this grant, Poulton beneficially owns 99,807 shares of Karyopharm common stock in direct ownership.
Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported the vesting of performance-based restricted stock units and a small share sale. On January 27, 2026, 92 shares of common stock were acquired at $0.0 upon PSUs vesting tied to revenue and total shareholder return milestones.
On January 28, 2026, Abate sold 50 shares of common stock at $7.03 per share to cover withholding tax from the PSU vesting under a pre-established automatic sale plan, described as non-discretionary. After these transactions, she directly owned 22,622 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc.'s Chief Accounting Officer, Kristin Abate, reported an automatic sale of company stock. On 01/21/2026, she sold 265 shares of common stock at $5.96 per share, leaving her with 22,580 shares held directly after the transaction.
The filing explains that this was a broker-assisted sale executed under a durable automatic sale instruction plan adopted on May 27, 2021. The sale was made solely to cover withholding tax liabilities arising from the vesting of restricted stock units and is described as not a discretionary trade by the reporting person.
Karyopharm Therapeutics (KPTI) reported a Form 4 showing Chief Accounting Officer Kristin Abate received 12,799 restricted stock units (RSUs) on October 15, 2025 at a stated price of $0. The RSUs convert into common stock on a one-for-one basis.
According to the award terms, 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026. Following this award, Abate beneficially owned 22,845 shares, reported as Direct (D) ownership.
Karyopharm Therapeutics (KPTI) reported an insider equity grant on a Form 4. EVP, Chief Development Officer Stuart Poulton received 39,682 restricted stock units (RSUs) on 10/15/2025 under the company’s 2022 Equity Incentive Plan at a reported price of $0. The RSUs convert to common stock on a one‑for‑one basis and vest 100% on December 31, 2026.
Following the grant, his direct beneficial ownership was 67,392 shares. This filing documents a routine equity award to a company officer.
Karyopharm Therapeutics (KPTI) reported an insider equity award for its President and CEO, Richard Paulson, on 10/15/2025. He received 114,285 restricted stock units at $0 under the company’s 2022 Equity Incentive Plan. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the grant, Paulson’s beneficial ownership totaled 198,331 common shares, held directly. He is also listed as a director.
Karyopharm Therapeutics (KPTI) reported an officer equity grant. SVP, General Counsel & Secretary Michael Mano received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. Each RSU converts into one share of common stock and vests 100% on December 31, 2026. Following the award, the reporting person beneficially owned 65,075 shares directly.
Karyopharm Therapeutics (KPTI) reported an executive equity award on a Form 4. EVP & Chief Commercial Officer Sohanya Cheng received 43,650 restricted stock units (RSUs) on 10/15/2025 at $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, Ms. Cheng beneficially owns 79,506 shares directly.
Karyopharm Therapeutics (KPTI) reported an insider equity grant: EVP, CFO & Treasurer Lori Macomber received 43,650 restricted stock units (RSUs) on 10/15/2025 at a price of $0. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the award, her beneficial ownership stands at 54,316 shares. The reported share amounts reflect the company’s one‑for‑fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics (KPTI) reported an insider transaction by its Chief Accounting Officer, Kristin Abate. On 10/01/2025, Abate sold 362 shares of common stock at a weighted average price of $6.296. Following the sale, she beneficially owned 10,046 shares directly.
According to the filing, the broker-assisted sale was executed under a durable automatic sale instruction plan adopted on May 27, 2021, to satisfy withholding taxes upon the vesting of PSUs, and does not represent a discretionary trade.
Richard A. Paulson, President, CEO and a director of Karyopharm Therapeutics (KPTI), reported the vesting of 2,800 performance-based restricted stock units (PSUs) on September 12, 2025. These PSUs were granted in February 2023 and were earned after the Compensation Committee certified completion of enrollment in the company’s Phase 3 SENTRY trial; each earned PSU represents the contingent right to one share and vested upon certification. Following vesting, a broker-assisted sale executed under an automatic sale instruction plan sold 1,257 shares on September 15, 2025 at $6.43 per share to satisfy withholding tax obligations. After these transactions, the reporting person beneficially owned 84,046 shares.
Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics (KPTI), reported that 612 performance-based restricted stock units (PSUs) were certified as earned and vested following achievement of a clinical enrollment milestone for the company’s Phase 3 SENTRY trial, converting into the contingent right to the same number of common shares. To satisfy tax withholding on the vested PSUs, the reporting person executed a broker-assisted sale of 234 shares at an average price of $6.43, leaving beneficial ownership of 21,425 shares.
Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics (KPTI), reported the vesting of 888 performance-based restricted stock units (PSUs) on 09/12/2025 after the company certified completion of enrollment in its Phase 3 SENTRY trial. Each PSU converts to one share, increasing his beneficial ownership to 28,111 shares. On 09/15/2025 he executed an automatic, broker-assisted sale of 401 shares at $6.43 to cover withholding taxes, leaving 27,710 shares beneficially owned. The PSUs were originally granted in February 2023 and vested upon certification by the Compensation Committee. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Insider filings show that Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics (KPTI), had performance-based restricted stock units (PSUs) certified as earned and vested on September 12, 2025. The certification converted 945 PSUs into the contingent right to receive 945 shares of common stock, increasing her beneficial holdings to 29,798 shares. Three days later, on September 15, 2025, Rangwala executed a broker-assisted sale of 408 shares at $6.43 per share under an automatic sale instruction plan to satisfy withholding tax liabilities related to the PSU vesting, leaving her with 29,390 shares beneficially owned.
Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics (KPTI), reported the vesting of performance-based restricted stock units tied to a clinical enrollment milestone and a subsequent small sale to cover taxes. The issuer certified that PSUs granted in February 2023 were earned based on achieving complete enrollment in the company\'s Phase 3 SENTRY trial; 945 earned PSUs vested and each represents the right to one common share. Following vesting, the reporting person beneficially owned 36,181 shares, which includes 922 shares purchased under the company\'s employee stock purchase plan. A broker-assisted sale of 325 shares at $6.43 per share was executed under an automatic sale instruction to satisfy withholding tax obligations incurred on the vested PSUs.
Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics Inc. (KPTI), reported the vesting of performance-based restricted stock units and a small subsequent sale. On September 12, 2025 the company certified that the clinical milestone for complete enrollment in its Phase 3 SENTRY trial had been achieved, resulting in 46 earned PSUs (each convertible into one share) which vested that day. The reporting line shows 10,431 shares beneficially owned following vesting (including 922 shares acquired via the ESPP on April 30, 2025). On September 15, 2025 the reporting person sold 23 shares at $6.43 per share under a pre-established automatic sale instruction to satisfy tax withholding obligations.